Welcome to our dedicated page for JUPITER NEUROSCIENCES SEC filings (Ticker: JUNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
Jupiter Neurosciences, Inc. is soliciting proxies for its 2026 virtual Annual Meeting to be held on July 22, 2026. Stockholders of record as of June 15, 2026 may vote on the election of seven directors, ratification of Cherry Bekaert LLP as auditor, a 2025 Plan amendment to add 5,250,000 shares, and a proposed Reverse Stock Split at a ratio between 1:10 and 1:100, with the exact ratio and timing left to the Board’s discretion.
The proxy packet includes the 2025 Annual Report and details on governance, board nominees, executive compensation, and procedures for virtual attendance and voting. The Board recommends approval of each proposal.
Jupiter Neurosciences filed a Prospectus Supplement dated June 5, 2026 updating its S-1 with a Form 8-K. The Form 8-K reports that Alison Silva was appointed Chief Operating Officer and President and her annual base salary was increased to $340,200.
The Board approved a one-time option grant to Ms. Silva for up to 600,000 shares, director option grants of up to 100,000 shares each, discretionary option grants listed for five executives (amounts shown in the filing), and an additional 200,000-share option grant to Mr. Elmasri. Option grants vest over three years beginning September 2, 2026 in equal quarterly installments, with exercise prices set at the closing market price on the grant dates. The prospectus supplement attaches the Form 8-K and the amendment to Ms. Silva’s employment agreement.
Jupiter Neurosciences, Inc. updated executive and director compensation, emphasizing stock-based incentives under its 2025 Equity Incentive Plan. Alison Silva was appointed Chief Operating Officer and President and her base salary increased to $340,200 from $315,000.
Silva received options to purchase up to 600,000 shares, while each independent non-employee director received options for 100,000 shares. The Board also granted discretionary bonus options in lieu of cash to several executives, including 747,783 options to CEO Christer Rosén and 427,304 options to Silva, plus an additional 200,000 options to CFO Saleem Elmasri. These options generally vest over three years starting on September 2, 2026 in equal quarterly installments.
JUPITER NEUROSCIENCES, INC. director Brady Allison W received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan. The options vest over three years starting September 2, 2026, in equal quarterly installments, and require continued service through each vesting date. Following this award, the filing shows 100,000 derivative securities held directly.
JUPITER NEUROSCIENCES, INC. reported a compensation-related stock option grant to its Chief Financial Officer, Saleem Elmasri. He received options for 525,565 shares of common stock at an exercise price of $0.2783 per share, expiring on June 2, 2036.
According to the disclosure, 325,565 options were granted as a discretionary bonus for services during fiscal 2025 and 200,000 options were granted as long-term incentive compensation under the 2025 Equity Incentive Plan. The options vest over three years starting from September 2, 2026 in equal quarterly installments, conditioned on continued employment through each vesting date.
Jupiter Neurosciences CEO and Chairman Christer Rosen received a grant of 747,783 stock options for common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036, giving him the right to buy shares at that price in the future.
According to the disclosure, the options were granted under the company’s 2025 Equity Incentive Plan as a discretionary bonus for services during fiscal 2025. They vest over three years starting on September 2, 2026, in equal quarterly installments, contingent on Rosen’s continued employment.
Jupiter Neurosciences director Nicholas H. Hemmerly received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036. They were granted under the company’s 2025 Equity Incentive Plan and vest over three years beginning on September 2, 2026, in equal quarterly installments, subject to his continued service through each vesting date. Following this grant, Hemmerly holds options for 100,000 underlying shares directly.
JUPITER NEUROSCIENCES, INC. director Julie B. Kampf received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
These options were granted under the company’s 2025 Equity Incentive Plan. They vest over three years in equal quarterly installments, beginning on September 2, 2026, as long as she continues to provide service through each vesting date. Following this grant, her reported option holdings from this award total 100,000 shares.
JUPITER NEUROSCIENCES, INC. reported that President and COO Alison D. Silva received a grant of stock options covering 1,027,304 shares of common stock at an exercise price of $0.2783 per share.
According to the footnote, 427,304 of these options were granted as a discretionary bonus for services during fiscal 2025, and 600,000 options were granted as long-term incentive compensation under the company’s 2025 Equity Incentive Plan. The options vest over three years, in equal quarterly installments starting on September 2, 2026, subject to continued employment, and this grant brings Silva’s reported derivative holdings to 1,027,304 options.
Jupiter Neurosciences, Inc. reported that Chief Scientific Officer Hayward Marshall received a grant of 259,231 stock options on June 2, 2026 as a discretionary bonus for services during fiscal 2025. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The options relate to 259,231 shares of common stock and were granted under the company’s 2025 Equity Incentive Plan. They vest over three years starting September 2, 2026, in equal quarterly installments, contingent on Mr. Marshall’s continued employment, and his total options following this grant are 259,231.